Document is current
Any future updates will be listed below
-
Authors
Hørsdal, Oskar Kjærgaard https://orcid.org/0000-0003-1009-3768
Larsen, Alexander Møller https://orcid.org/0009-0000-4459-4291
Wethelund, Kasper Lykke https://orcid.org/0009-0003-3014-083X
Dalsgaard, Frederik Flyvholm https://orcid.org/0000-0002-7287-9793
Seefeldt, Jacob Marthinsen https://orcid.org/0000-0002-0633-5878
Helgestad, Ole Kristian Lerche https://orcid.org/0000-0003-3847-8758
Moeslund, Niels https://orcid.org/0000-0003-0827-5263
Møller, Jacob Eifer https://orcid.org/0000-0003-2873-5845
Ravn, Hanne Berg https://orcid.org/0000-0003-4702-5195
Nielsen, Roni Ranghøj https://orcid.org/0000-0001-9228-3869
Wiggers, Henrik https://orcid.org/0000-0002-9753-4142
Berg-Hansen, Kristoffer https://orcid.org/0000-0002-5110-0656
Gopalasingam, Nigopan https://orcid.org/0009-0006-6363-7406
-
Funding
Funding for this research was provided by:
Novo Nordisk (NNF17OC0028230, NNF21SA0069371)
Aase og Ejnar Danielsens Fond
Direktør Emil C. Hertz og Hustru Inger Hertz Fond
Sundhedsvidenskabelige Fakultet, Aarhus Universitet
Aarhus Universitet
- License Information
-
More Information
Article History
Received: 10 January 2025
Revised: 17 March 2025
Accepted: 19 March 2025
First Online: 12 April 2025
Declarations
:
: Henrik Wiggers has been the principal or a sub-investigator in studies involving the following pharmaceutical companies: MSD, Bayer, Daiichi-Sankyo, Novartis, Novo Nordisk, Sanofi-Aventis, and Pfizer. Jacob Eifer Møller has been the principal investigator in studies involving Abiomed. The other authors have no conflicts of interest to report.
: The study was conducted following requisite authorization from the Danish national Animal Experiment Inspectorate (Hemodynamic Optimization with Carbonates, Permit no: 2023-15-0201-01466. Issue date: 19/06-2023). The treatment and ethical oversight of the animals strictly adhered to established animal welfare protocols and regulatory standards stipulated by both Danish and European legislation. The methodologies and animal handling conformed to the EU Directive 2010/63/EU pertaining to animal experimentation. The study followed the ARRIVE 2.0 guidelines.
